LAX.SH
IND SWIFT LABORATORIES LT·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
345.35
+0.83%52W Range
Market Cap
₹3,003.22 Cr
Traded: ₹9.25 Cr (0.31%) 0.0x
Free Float: ₹1,159.54 Cr (0.80% of FF traded)
Volume · 60D trend
2.7 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +0.0% | -6.0% | -19.0% | -- | +14.0% | Stable |
| Profit | +12.0% | +78.0% | -7.0% | -- | +2695.0% | Stable |
| Return | +13.0% | +10.0% | +24.0% | +70.0% | -- | Accelerating |
| ROE | +3.0% | +6.0% | +7.0% | -- | -- | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 191 | 170 | 151 | 153 | 153 | 138 | 129 | 12 | 33 | 529 | 288 | 290 | 310 | 304 | 313 | 310 |
| Expenses | 158 | 149 | 147 | 151 | 149 | 147 | 135 | 24 | 43 | 437 | 236 | 224 | 250 | 241 | 259 | 251 |
| Operating Profit | 33 | 21 | 4 | 1 | 4 | -9 | -7 | -12 | -10 | 91 | 52 | 66 | 60 | 64 | 54 | 59 |
| Other Income | 7 | -3 | 22 | 18 | 15 | 220 | 16 | 13 | 11 | 458 | 7 | 7 | 6 | -16 | 8 | 8 |
| Interest | 1 | -2 | 1 | 2 | 1 | -27 | 10 | 0 | 0 | 3 | 21 | 21 | 20 | 22 | 22 | 24 |
| Depreciation | 8 | 8 | 9 | 7 | 7 | 7 | 6 | 0 | 0 | 20 | 14 | 13 | 14 | 9 | 15 | 16 |
| Profit Before Tax | 33 | 12 | 16 | 10 | 10 | 230 | -7 | 1 | 1 | 527 | 24 | 39 | 32 | 16 | 24 | 26 |
| Tax % | 25.0% | -26.0% | 42.0% | 22.0% | 17.0% | 4.0% | -16.0% | 31.0% | -3.0% | 6.0% | 19.0% | 18.0% | 45.0% | 255.0% | -13.4% | 2.2% |
| Net Profit | 25 | 15 | 10 | 8 | 9 | 222 | -5 | 0 | 1 | 494 | 19 | 32 | 17 | -25 | 28 | 25 |
| Exceptional Items | -- | -5 | -6 | 0 | 0 | 216 | -1 | 0 | 0 | 387 | 0 | 0 | 0 | -27 | 0 | 0 |
| EPS (Rs) | 2.8 | 1.7 | 1.2 | 1.0 | 1.4 | 36.7 | -0.9 | 0.1 | 0.2 | 83.5 | 3.3 | 5.4 | 2.9 | -4.3 | 4.7 | 4.3 |
| Sales Growth (YoY) | -- | 22.8% | 17.1% | 1176.3% | 360.4% | -73.8% | -55.2% | -95.9% | -89.3% | 73.7% | -8.1% | -6.6% | 10.8% | -0.8% | -- | -- |
| Sales Growth (QoQ) | -- | 12.6% | -1.3% | 0.0% | 10.9% | 7.0% | 975.0% | -63.6% | -93.8% | 83.7% | -0.7% | -6.5% | 2.0% | -2.8% | 0.8% | -- |
| OP Growth (YoY) | 725.0% | 333.3% | 157.1% | 108.3% | 140.0% | -109.9% | -113.5% | -118.2% | -116.7% | 42.2% | -3.3% | 12.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 57.1% | 425.0% | 300.0% | -75.0% | 144.4% | -28.6% | 41.7% | -20.0% | -111.0% | 75.0% | -21.2% | 10.0% | -6.3% | 19.0% | -8.5% | -- |
| Profit Growth (YoY) | -- | 9.3% | 371.9% | 1848.8% | 833.0% | -87.3% | -124.5% | -98.7% | -94.5% | 450.7% | -29.4% | 24.9% | -13.3% | 35.5% | 72.0% | 4.0% |
| EPS Growth (YoY) | -- | -95.3% | 225.8% | 1300.0% | 806.3% | -56.1% | -128.3% | -98.7% | -94.5% | 2065.9% | -29.3% | 24.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 48.7% | 19.4% | -32.4% | -96.0% | 4043.0% | -1428.6% | -56.3% | -99.8% | 2439.5% | -38.6% | 83.6% | 168.7% | -191.4% | 8.4% | -- |
| OP Margin | -- | 12.3% | 2.6% | 0.7% | 2.6% | -6.5% | -5.4% | -100.0% | -30.3% | 17.2% | 18.1% | 22.8% | 19.4% | 21.1% | 17.2% | 18.9% |
| Net Margin | -- | 8.8% | 6.6% | 5.2% | 5.9% | 160.9% | -3.9% | 0.0% | 3.0% | 93.4% | 6.6% | 11.0% | 5.5% | -8.2% | 8.8% | 8.2% |
| Material Cost % | -- | 36.2% | 46.6% | 50.9% | 47.9% | 41.7% | 47.9% | 69.5% | 82.3% | 50.5% | 54.1% | 49.9% | 52.3% | 53.4% | 58.4% | 54.0% |
| Employee Cost % | -- | 21.9% | 21.2% | 23.8% | 21.3% | 22.7% | 23.0% | 48.5% | 18.4% | 11.7% | 12.9% | 12.9% | 12.6% | 11.7% | 10.6% | 11.0% |
| P/S | 4.52 | 3.29 | 1.97 | 2.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 51.32 | 44.43 | 3.35 | 3.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.17 | 1.49 | 0.89 | 0.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve inter alia, to Consider ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others
Please refer attached pdf.
Please find enclosed newspaper clippings informing stakeholders regarding special window for relodgement of physical shares
Please find enclosed scrutiniser''s report along with voting results for the 31st AGM, held on 30th September, 2026
Please refer the attached pdf
Please find enclosed proceedings of the 31st Annual General Meeting of the company held on Wednesday, 30th Sept., 2026.
Please refer the attached pdf.
Please find enclosed Schedule of Analyst / Investor Meet scheduled to be held on Tuesday, 29th September, 2026, at 01.00 P.M. IST
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others
Please refer attached pdf.
Outcome of Preferential Issue Committee for Allotment of 70,00,000 Fully Convertible Warrants on Preferential Basis
Please refer enclosed pdf.
Notice of the 31st AGM of the company scheduled to be held on Wednesday, 30.09.2026, at 03:00 P.M. through VC/OAVM.
Please find enclosed Annual Report for the FY 2025-26.
Please refer attached pdf.
Please refer attached newspaper publication dated 04.09.2026.
Please find enclosed outcome of Board Meeting held on September 02, 2026.
The Exchange has sought clarification from Ind-Swift Laboratories Ltd on August 27, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Please refer attached pdf regarding clarification sought from company regarding movement in value .
Please find enclosed Transcript of Earning Call held on August 17, 2026.
Please find enclosed press release titled as Ind-Swift to make Jammu facility EUGMP and PICS Compliant targets additional revenue of 100 crores from 2029-30 onwards .
Please find attached intimation regarding the investor presentation on un-audited financial results for the quarter ended June, 30 2026.
Audio recording of earning conference call held on 17.08.2026 on un-audited financial results for the quarter ended 30.06.2026.
Please refer attached pdf .
Please find enclosed report of the Monitoring Agency for the quarter ended June 30, 2026.
Please find enclosed Schedule of Analyst / Investor Meet will be held on Monday, 17th August, 2026, at 03.00 P.M. IST in respect of financial results of the Company for the quarter ended ....
Please find enclosed outcome of the Board Meeting Dated August 10, 2026
Please find enclosed Statement of NIL Deviation for the Quarter ended June 30, 2026
please refer attached pdf.
Please find enclosed voting results along with scrutinizer''s report
Please refer attached pdf
Please find attached proceedings of EGM which was held today i.e., on 5th August, 2026
Please refer attached pdf.
Newspaper Publication regarding dispatch of Notice calling Extra Ordinary General Meeting schedule to be held on 5th August, 2026.
Please refer attached pdf.
Please refer attached pdf.
Please refer attached pdf
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/07/2026 ,inter alia, to consider and approve raising of funds by ....
Please refer attached pdf.
Please refer attached pdf.
Please refer enclosed pdf.
Please refer attached pdf.
Please refer attached pdf.
Please refer attached pdf.
Audited Financial results for the Quarter and Financial year ended 31st March 2026
Please refer attached pdf.
Please refer attached pdf.
Intimation of allotment of 1,25,000 equity shares pursuant to ESOP, 2014.
Ind-Swift Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve and take on record Standalone ....
Annual Reports
14Credit Ratings
6Held by ETFs
1 ETFs hold indswftlab · sorted by weight